RxDoctor Payments Data

Mhd Zakaria, MD

Internal Medicine · Palos Heights, ILNPI 1912218272

Payments from drug & device makers

$7,527in general payments, 2019–2025

Across 387 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$998
  • Pfizer$834
  • AstraZeneca$828
  • GSK$661
  • Bayer$473
  • Lilly USA, LLC$445
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$7,495100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,527 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$712,508
Medicare patients
991
Services billed
7,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban479$291,036
FarxigaDapagliflozin Propanediol121$96,120
RybelsusSemaglutide67$87,047
JardianceEmpagliflozin78$86,659
OzempicSemaglutide61$74,499
MounjaroTirzepatide50$58,969
JanuviaSitagliptin Phosphate67$55,294
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$45,456
XareltoRivaroxaban102$41,227
EntrestoSacubitril/Valsartan65$37,524
KerendiaFinerenone23$23,822
TradjentaLinagliptin67$21,838
TrulicityDulaglutide15$15,595
Atorvastatin Calcium1,260$13,671
Breo ElliptaFluticasone/Vilanterol19$9,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$834$291,036479 claims
Novo NordiskRybelsus, Ozempic$998$161,546128 claims
Boehringer IngelheimJardiance, Tradjenta$220$108,496145 claims
AstraZenecaFarxiga, Brilinta, Symbicort$828$107,686161 claims
Lilly USA, LLCMounjaro, Trulicity$445$74,56565 claims
MerckJanuvia, Janumet Xr$196$61,83979 claims
GSKTrelegy Ellipta, Breo Ellipta$661$55,15468 claims
Johnson & JohnsonXarelto$139$41,227102 claims
NovartisEntresto$258$37,52465 claims
BayerKerendia$473$23,82223 claims
Astellas Pharma US IncMyrbetriq$51$9,04315 claims
Sanofi-aventis U.S. LLCLantus$64$3,31944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Palos Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →